- In April 2024, Elanco Animal Health Incorporated announced the launch of a new chewable NSAID tablet designed specifically for long-term osteoarthritis management in dogs. The product, developed with advanced COX-selective inhibition technology, aims to minimize gastrointestinal side effects while providing sustained pain relief. This launch reinforces Elanco’s commitment to addressing chronic pain in companion animals with innovative, safe, and palatable formulations that enhance treatment adherence and clinical outcomes
- In March 2024, Zoetis Inc. expanded its Solensia product line in Europe, introducing a monthly injectable monoclonal antibody therapy as an alternative to traditional NSAIDs for feline osteoarthritis. While not an NSAID itself, the product’s success underscores the growing demand for advanced pain management and complements NSAID offerings in multimodal treatment protocols. The move reflects Zoetis’ strategic investment in differentiated, species-specific pain solutions for underserved animal segments
- In February 2024, Boehringer Ingelheim launched an extended-release injectable NSAID for cattle in key Latin American markets. The formulation is designed to provide multi-day relief from pain and inflammation associated with common veterinary procedures such as castration and lameness treatment. This development highlights the company's focus on improving livestock welfare and productivity, in line with evolving regional animal health regulations and ethical farming practice
- In January 2024, Vetoquinol announced regulatory approval for its new oral NSAID in several Southeast Asian countries, targeting pain associated with musculoskeletal conditions in dogs. This expansion strengthens Vetoquinol’s presence in emerging markets and provides veterinarians with more affordable, convenient treatment options. The company aims to bridge the accessibility gap in veterinary pain management by combining clinical efficacy with regional market adaptability
- In December 2023, Ceva Santé Animale entered into a strategic collaboration with a biotechnology firm to explore the development of next-generation NSAID alternatives using nanocarrier technology. The initiative focuses on improving drug bioavailability and minimizing systemic side effects in small animals. This partnership underscores Ceva’s dedication to innovation in veterinary pain relief and its long-term strategy to evolve beyond traditional NSAID formulations.
